Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was incorporated in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma LLC.
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]
Pomerantz LLP is investigating claims on behalf of investors of Eidos Therapeutics, Inc. (“Eidos” or the “Company”) (NASDAQ: EIDX). The investigation concerns whether Eidos and certain of its officers and/or directors have breached fiduciary duties owed to the company and its investors. If you are a shareholder of Eidos and are interested in obtaining additional information regarding this investigation, you are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.